Indeed, SPMs such as resolvins have entered clinical development for inflammatory diseases. 8 Most recently, they were also shown efficient at suppressing therapy-induced tumor growth in a preclinical model. 8 It would be especially relevant to assess whether these drugs could dampen the biomarkers of aging associated with past radiotherapy and/or chemotherapy, and limit or delay the onset of secondary malignancies as patients age.
It may seem counterintuitive to consider that cancer therapies could contribute to the relapse of the disease they were intended to treat. 9 However, accumulating evidence suggest that efficient treatment regimens, as they are currently delivered, can also have multiple long-and late-term pro-tumorigenic side effects, 3, 8, 10 some not yet discovered. Given the continuous growth in the number of cancer survivors, this is an issue we urgently need to address.
Indeed, a long-awaited paradigm shift is occurring: therapyinduced pathways are now being considered as potential therapeutic targets.
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